Valneva SE (VALN) Liabilities and Shareholders Equity (2020 - 2026)
Valneva SE (VALN) posted Liabilities and Shareholders Equity of $435.5 million for Q1 2026, down 6.19% sequentially from $464.3 million in Q4 2025, and down 14.14% YoY from $507.3 million in Q1 2025.
Analysis
Valneva SE (VALN) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Valneva SE has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $435.5 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 14.14% year-over-year to $435.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 billion (down 7.23% YoY) and the FY2025 annual result came in at $464.3 million, down 14.22% from the prior year.
- Liabilities and Shareholders Equity eased to $435.5 million in Q1 2026 per VALN's latest filing, from $464.3 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $872.9 million in Q1 2022 and troughed at $435.5 million in Q1 2026.
- A 5-year average of $581.6 million and a median of $546.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity sank 32.2% in 2022, then advanced 7.95% in 2024.
- Over 5 years, Liabilities and Shareholders Equity stood at $633.9 million in 2022, then decreased by 21.92% to $495.0 million in 2023, then rose by 7.95% to $534.3 million in 2024, then fell by 13.11% to $464.3 million in 2025, then dropped by 6.19% to $435.5 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $435.5 million, $464.3 million, and $524.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | 451.32 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 451.32 Mn |
| Mar 31, 2026 | 435.53 Mn |
| Dec 31, 2025 | 464.26 Mn |
| Sep 30, 2025 | 524.00 Mn |
| Jun 30, 2025 | 534.99 Mn |
| Mar 31, 2025 | 507.26 Mn |
| Dec 31, 2024 | 534.33 Mn |
| Sep 30, 2024 | 567.36 Mn |
| Jun 30, 2024 | 502.44 Mn |
| Mar 31, 2024 | 546.25 Mn |
| Dec 31, 2023 | 495.00 Mn |
| Sep 30, 2023 | 566.65 Mn |
| Jun 30, 2023 | 590.82 Mn |
| Mar 31, 2023 | 633.27 Mn |
| Dec 31, 2022 | 633.92 Mn |
| Sep 30, 2022 | 703.86 Mn |
| Jun 30, 2022 | 773.73 Mn |
| Mar 31, 2022 | 872.85 Mn |
| Dec 31, 2021 | 935.03 Mn |
| Dec 31, 2020 | 535.53 Mn |